Marchisotti Frederico G, Carvalho Luciani R S, Berger Karina, Arnhold Ivo J P, Mendonça Berenice B
Unidade de Endocrinologia do Desenvolvimento, Laboratório de Hormônios e Genética Molecular-LIM/42, Hospital das Clínicas, FMUSP, São Paulo, SP.
Arq Bras Endocrinol Metabol. 2007 Oct;51(7):1093-6. doi: 10.1590/s0004-27302007000700011.
The aim of this study was to compare two preparations of recombinant human GH (rGH) in the treatment of GH deficient patients. Ten prepubertal GH-deficient children were followed during 6 months. They received injections with syringe for 3 months, followed by pen administration for the subsequent 3 months. Acceptability was evaluated through a questionnaire. Waste of medication was calculated by the difference between the number of used bottles or refills and the calculated amount for the period. Treatment response was evaluated by SDS gain of height measured each 3 months. After 6 months, 90% of patients/family members declared they preferred the pen regarding technical facility and local pain, and all patients considered the pen easier to transport and store. The waste of medication was lower with pen administration, as was the final cost. We concluded that pen-administered rGH treatment is more convenient, better accepted by the patients, and leads to less waste of medication when compared to the syringe administration.
本研究的目的是比较两种重组人生长激素(rGH)制剂在治疗生长激素缺乏患者中的效果。10名青春期前生长激素缺乏儿童接受了为期6个月的随访。他们先用注射器注射3个月,随后3个月使用笔式注射器给药。通过问卷调查评估可接受性。药物浪费通过已使用药瓶或补充装的数量与该时间段计算用量之间的差值来计算。每3个月测量身高的标准差得分以评估治疗反应。6个月后,90%的患者/家庭成员表示,就技术便利性和局部疼痛而言,他们更喜欢笔式注射器,且所有患者都认为笔式注射器更便于携带和储存。笔式注射器给药的药物浪费更少,最终成本也更低。我们得出结论,与注射器给药相比,笔式注射器注射rGH治疗更方便,患者接受度更高,且药物浪费更少。